Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical Stem Cell Transplantation for Germline RUNX1 Associated Hematologic Malignancies
NCT07524530Phase 2Not yet recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2026
- Primary completion
- Jun 2033
- Countries
- 1
01
Overview
A Phase 2 trial of hematopoietic stem cells in hematologic malignancy, sponsored by National Cancer Institute. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
hematopoietic stem cells
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT07524530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07524530.